|
PT
|
PT3
|
PT7
|
PT11
|
PT14
|
Median of PTs
|
HD1
|
HD2
|
Median of HDs
|
|---|
|
Days Post Tx
|
D98
|
D561
|
D456
|
D596
|
D448
|
|---|
|
PD-L1 + CD4
|
1.9
|
1.2
|
1.5
|
1.6
|
1.5
|
1.5
|
0.7
|
0.5
|
0.6
|
|
PD-L1 + CD8
|
0.9
|
0.9
|
0.6
|
1.1
|
1.8
|
0.9
|
1.6
|
0.8
|
1.2
|
|
PD-L1 + Treg
|
0.3
|
0.1
|
0.8
|
0.6
|
0.6
|
0.6
|
0.2
|
0.1
|
0.2
|
|
PD-L1 + NK
|
3.1
|
1.8
|
1.3
|
1.3
|
1.6
|
1.6
|
1.0
|
0.5
|
0.8
|
|
PD-L1 + NKT
|
38.2
|
1.5
|
0.8
|
0.8
|
1.6
|
1.5
|
2.2
|
0.9
|
1.5
|
|
PD-L1 + B cells
|
19.45
|
6.75
|
14.12
|
12.83
|
13.14
|
13.1
|
29.32
|
14.00
|
21.7
|
|
PD-L1 + cDc
|
25.6
|
2.2
|
2.5
|
3.3
|
5.5
|
3.3
|
4.3
|
1.3
|
2.8
|
|
PD-L1 + pDc
|
< 0.01
|
< 0.01
|
< 0.01
|
< 0.01
|
< 0.01
|
< 0.01
|
< 0.01
|
< 0.01
|
< 0.01
|
|
PD-L1 + MDSC
|
19.34
|
11.81
|
10.12
|
11.42
|
15.11
|
11.8
|
4.37
|
5.76
|
5.1
|
- Expression of PD-L1 in 9 classic subsets was measured by flow cytometry in 4 patients, where PBMCs were available, after treatment with durvalumab and olaparib. Results are displayed as % of classic subsets that express PD-L1. cDC conventional dendritic cells, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PD-L1 programmed cell death ligand-1, Tregs regulatory T cells
